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Abstract: Objective: The cannabinoid receptor 2 (CB2) has been implicated to play a role in various inflammatory proc-
esses. Since atherosclerosis is currently considered a chronic inflammatory disease, we studied the effect of haema-
topoietic CB2 deficiency on atherosclerosis development. 
Methods and results: To investigate the effect of CB2 deficiency in immune cells on atherogenesis in vivo, a bone marrow 
transplantation was performed in irradiated LDL receptor deficient mice (LDLr
-/-), using CB2 deficient (CB2
-/-) or wild-
type (WT) donor mice. After 12 weeks on a high fat-high cholesterol diet, en face analysis showed that atherosclerosis in 
the aortic arch was significantly increased in CB2
-/- transplanted animals (6.40 ± 3.21%) as compared to WT transplanted 
mice (3.85 ± 1.61%). Although the total lesion area in the aortic root was not significantly different between WT and 
CB2
-/- transplanted mice (0.45 ± 0.13 mm
2 and 0.51 ± 0.17 mm
2, respectively), CB2
-/- transplanted mice showed a signifi-
cantly larger plaque area (0.13 ± 0.07 mm
2) than WT transplanted mice (0.08 ± 0.05 mm
2) in the aortic valve in which 
atherogenesis is in an earlier stage than in the other aortic valves. 
Conclusions: Lack of endocannabinoid signaling via the CB2 receptor aggravates early atherosclerosis development in 
LDLr
-/- mice, suggesting that CB2 specific activation may prevent the development of atherosclerosis. 
Keywords: Atherosclerosis, cannabinoid receptor, CB2, LDLr-/- mice.  
INTRODUCTION 
  Rather than simply a disease caused by elevated plasma 
lipid levels, atherosclerosis is nowadays also considered to 
be a chronic inflammatory condition [1-3]. Already at the 
onset of atherogenesis, monocytes from the circulation mi-
grate into the arterial wall to differentiate into macrophages, 
start to accumulate cholesterol and produce inflammatory 
mediators. The subsequent attraction of additional inflamma-
tory cells, migration and proliferation of smooth muscle 
cells, production of plaque destabilizing factors and necrosis 
can ultimately lead to acute coronary events, such as myo-
cardial infarction or stroke [4]. 
  Cannabinoids have been described to have immuno-
modulatory activities [5]. Since the cannabinoid receptor 1 
(CB1) is predominantly expressed in the central nervous 
system [6], and the cannabinoid receptor 2 (CB2) is highly 
expressed in immune cells [7], the immune regulatory effects 
of cannabinoids have been mainly ascribed to CB2. It needs 
to be reminded, however, that expression profiles for CB1  
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and CB2 are not mutually exclusive. Endogenous cannabi-
noids or synthetic ligands for cannabinoid receptors have 
been reported to modulate pro- and anti-inflammatory cyto-
kine production [5], inflammatory cell spreading [8], migra-
tion [9, 10] and B- and T-cell proliferation [11]. Also in 
more complex models of inflammation, such as oxazolone-
induced dermatitis [12] and collagen-induced arthritis in the 
mouse [13], cannabinoid receptor ligands have been shown 
to have potent anti-inflammatory effects (reviewed in [5]). 
  Recently, it was described that the cannabinoid derivative 

9-tetrahydrocannabinol (THC) is able to reduce atheroscle-
rosis development in apolipoprotein E knockout mice [14]. 
Subsequent in vitro investigations suggested that THC may 
exert its effect via inhibition of the TH1 response and reduc-
tion of monocyte migration [14]. Since the effects could be 
counteracted by a CB2 receptor antagonist, SR144528, the 
authors concluded that the effects of THC were mediated 
through CB2. It has, however, just now been described that 
THC also acts at peroxisome proliferator-activated receptor 
(PPARs), thereby potentially inducing cardioprotective ef-
fects [15]. 
  To rule out the possibility that the above mentioned im-
mune modulations might be caused or influenced by off-16    The Open Cardiovascular Medicine Journal, 2011, Volume 5  Delsing et al. 
target activity of cannabinoid compounds, we investigated 
the effect of CB2 receptor deficiency on atherosclerosis de-
velopment. The CB2 receptor deficient mouse has been de-
scribed to show compromised immunomodulation in vitro 
[16] and in vivo [17]. In the present study, a bone marrow 
transplantation was performed to specifically investigate the 
effect of haematopoietic CB2 deficiency, and thereby lack  
of endocannabinoid signaling via CB2, on atherosclerosis 
development in LDL receptor knockout mice. 
MATERIALS AND METHODOLOGY 
Animals 
  Female LDL receptor knockout mice (LDLr
-/-, n=40) 
were purchased from the Jackson Laboratory (Bar Harbor, 
MA, USA) and used as acceptor mice. CB2 receptor knock-
out mice (CB2
-/-) were obtained from Dr. Andreas Zimmer 
(University of Bonn, Germany) and bred at Schering-Plough, 
Oss. Both strains of mice had been backcrossed to the 
C57Bl/6 background for at least 10 generations. Male CB2
-/- 
mice (n=6) and wildtype (WT) controls (n=6) were used as 
donor mice for the bone marrow transplantation. All animals 
were kept on a regular chow diet (SDS, Special Diet Serv-
ices, Witham, UK), until the bone marrow transplantation. 
The experiments were approved by the Animal Welfare 
Committee of MSD, Oss. 
Bone Marrow Transplantation 
  Animals were maintained in filter-top cages and given 
acidified drinking water (pH=2.0) supplemented with neo-
mycin (100mg/l, Sigma) and polymyxin B sulfate (60.000 
U/l, Sigma) from 1 week before transplantation until 4 weeks 
after. 
  Prior to irradiation, the acceptor mice were anaesthetised 
by intraperitoneal injection with 100 mg/kg ketamine (Al-
fasan, The Netherlands) and 10 mg/kg xylazine (Eurovet, 
The Netherlands) in saline. Subsequently, animals were sub-
jected to 8 Gy of total body irradiation using a 
137Cs source 
(Gammacell 3000 Elan, MDS Nordion, Canada). One day 
after irradiation, acceptor mice were transplanted with bone 
marrow cells from either WT or CB2
-/- mice by injection of 1 
*10
7 donor cells into the tail vein. 
Atherosclerosis Study 
  Four weeks after transplantation, animals were put on a 
high fat diet (Arie Blok, Woerden, The Netherlands) contain-
ing 16% fat and 0.15% cholesterol. After 12 weeks on the 
diet, animals were sacrificed and the hearts and aortic arches 
were isolated for further analysis. Aortic arches and hearts 
were stored overnight in phosphate-buffered formalin solu-
tion (4%)  and the hearts were embedded in paraffin. The 
aortic arches were cut open via the outer curvature and fixed 
onto a silicone-covered petridish (Austerlitz insect pins 
0.025 mm, finescience.com). Subsequently, the tissue was 
stained with Oil Red O Sigma-Aldrich, Zwijndrecht, The 
Netherlands) and plaque size was quantified using a Zeiss 
Axioplan microscope and IDTCC software. Serial cross sec-
tions (4 m) of the heart throughout the entire aortic valve 
area were used for histological analysis. Sections were 
stained with haematoxylin-eosin (HE). Per mouse, 4 sections 
(with intervals of 40 m) were used for quantification and 
qualification of atherosclerotic lesions. For determination of 
severity of atherosclerosis, the lesions were classified into 
five categories (type I-V) as described before [18]: I) early 
fatty streak, II) regular fatty streak, III) mild plaque, IV) 
moderate plaque, V) severe plaque. In addition to plaque 
severity, the degree of collagen deposition, necrosis, mono-
cyte adherence, inflammatory infiltrations and large foam 
cell content was scored by an experienced pathologist (a 
score of 0-4 was assigned, MG). Lesions were qualified and 
quantified using a Zeiss Axioplan microscope and IDTCC 
software. 
Determination of Chimerism 
  To determine the chimerism in our transplanted mice we 
took advantage of the fact that the donor bone marrow is 
LDLr
WT, whereas recipient mice are LDLr
-/-. Chimerism was 
determined in 40 l peripheral blood samples by quantifying 
the amount of LDLr
-/- DNA relative to a control gene (p50). 
Genomic DNA was isolated using the GFX Genomic   
DNA Purification Kit (Amersham Pharmacia Biotech. Inc., 
Arlington Heights, IL, USA).The samples were assayed in  
duplicate using the TaqMan Universal PCR Master Mix   
and the ABI Prism 7900 HT Sequence Detection System 
(Applied Biosystems 2001) using 300 nM primer and 200 
nM probe. LDLr
-/- specific primer/probe set : forward 5’-
GCTGCA-ACTCATCCATATGCA-3’; reverse 5’-GGAGT-
TGTTGA-CCTCGACTCTAGAG-3’; probe 5’-6FAM-CCC-
CAGTC-TTTGGGCCTGCGA-TAMRA-3’. p50 specific pri-
mer-/probe set: forward 5’-AACCTGGGAAT-ACTTCAT-
GTGACTAA-3’; reverse 5’-GCACCAG-AAGTCCAGG-
ATTATAGC-3’; probe 5’-TET-TCCGTGC-TTCCAGTGT-
TTCAAATACCTTTTT-TAMRA-3’. 
Blood Analysis 
  After different periods of diet feeding 3,6,9 and 12 
weeks), blood was drawn via tail incision into heparinised 
glass capillaries Hirschmann Laborgeräte, Eberstadt, Ger-
many) following a 4-hour period of fasting. Plasma choles-
terol was determined using the Cholesterol Liquicolor assay 
(Instruchemie, The Netherlands) following manufacturers 
instructions. 
  For leukocyte analysis, heparinised blood samples were 
washed in erythrocyte lysis buffer (0.155 M NH4Cl, 10 mM 
NaHCO3). Samples were either stained with Mac1-PE and 
Gr1-FITC (BD Pharmingen, R&D Systems) for detection of 
macrophages (Mac1+, Gr1-) and granulocytes (Mac1+, 
Gr1+); or with B220-PE and CD3-FITC (BD Pharmingen) to 
detect B-cells (B220+) and T-cells (CD3+). As isotype con-
trols, rIgG2b-PE, rIgG2a-PE, arHamIg1-FITC (BD 
Pharmingen) and rIgG2b-FITC (R&D Systems) were used. 
Statistical Analysis 
  Statistical analysis of atherosclerotic plaque size in the 
aortic arch and root was performed using GraphPad Prism 
(Version 4.03, GraphPad Software Inc., San Diego, CA, 
USA). To test whether CB2
-/- transplanted mice had larger 
plaques in the aortic root or arch than WT transplanted ani-
mals, a one-sided non-parametric Mann-Whitney rank sum 
test was performed. To test whether CB2
-/- transplanted mice 
had a higher plaque severity than WT transplanted mice, a 
one-sided linear-by-linear association test was performed. As CB2 Deficiency Aggravates Early Atherosclerosis  The Open Cardiovascular Medicine Journal, 2011, Volume 5    17 
opposed to the Chi-square test, this test accounts for the or-
dinality of plaque severity. The same test was used for the 
association between transplant type and pathology scores, 
but since here the direction of the effect is not anticipated, 
two-sided p-values are reported. These tests were performed 
using the library 'coin' from the statistical software R (R   
Development Core Team (2007); http://www.R-project.org). 
P values less than 0.05 were regarded significant. 
RESULTS 
No Influence of CB2 Deficiency on Body Weight, Plasma 
Cholesterol Levels, Chimerism and Blood Leukocyte 
Composition 
  Bone marrow cells from CB2
-/- or WT mice were trans-
planted into lethally irradiated LDLr
-/- mice, to yield chi-
meric LDLr
-/- mice with either CB2
-/- or WT blood leuko-
cytes. The body weight of all animals decreased on average 
by 15% within 5 days after irradiation, returning to pre-
irradiation levels within 10 days after the transplantation. 
There were no differences in body weight between CB2
-/- 
and WT transplanted animals (data not shown). 
  To determine whether the transplantation had an effect 
on blood leukocyte composition, FACS-analysis was per-
formed on blood samples drawn 5 weeks after transplanta-
tion. As shown in Table 1, the percentages of blood granulo-
cytes, monocytes, T-cells and B-cells were not significantly 
different between CB2
-/- and WT transplanted animals.   
Furthermore, quantitative PCR analysis showed that on   
average 94% of leukocytes were of donor origin in both 
groups, indicating a successful engraftment. 
  After 3 weeks of high fat diet feeding, plasma cholesterol 
levels were 25.8 ± 2.1 mmol/l in the CB2
-/- transplanted 
group and 23.5 ± 2.8 mmol/l in the WT transplanted group. 
In the course of high fat diet feeding, plasma cholesterol 
levels slightly increased to about 30 mmol/l, but were never 
significantly different between CB2
-/- and WT transplanted 
animals (Fig. 1). 
CB2 deficiency enhances early atherosclerotic plaque 
formation in the aortic arch and root 
  To investigate the role of CB2 in atherosclerotic lesion 
formation, the lesion area in the aortic arch was determined 
by en face analysis of oil red O stained tissue (Fig. 2A). In-
terestingly, the percentage of the aortic arch covered with an 
atherosclerotic lesion was significantly higher in CB2
-/- 
transplanted animals (6.40 ± 3.21%) than in WT transplanted 
animals (3.85 ± 1.62%) (Fig. 2B), indicating that haema-
topoietic CB2 deficiency enhanced atherosclerosis develop-
ment in the aortic arch. 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Plasma cholesterol levels of LDLr-/- transplanted with WT 
bone marrow (n=18) or CB2-/- bone marrow (n=17) measured in 
time during high fat diet feeding. 
  To determine whether this also holds true at other loca-
tions in the vasculature, the aortic root of all mice was ana-
lyzed. Cross-sections of atherosclerotic plaques found in the 
aortic root of WT and CB2
-/- transplanted LDLr
-/- mice are 
shown in (Fig. 3A). Atherosclerotic lesions were very ad-
vanced in both groups, and many contained large numbers of 
foam cells and inflammatory infiltrates and a necrotic core. 
Analysis of lesion size in the aortic root showed that haema-
topoietic deficiency of CB2 had no significant effect on the 
total atherosclerotic lesion area (Fig. 3B). The average lesion 
area was 0.51 ± 0.17 m
2 in the CB2
-/- transplanted group 
and 0.45 ± 0.13 m
2 in the WT transplanted group. We know 
from experience in this model, that one of the three aortic 
valves demonstrates delayed atherosclerosis development 
compared to the other two. Indeed, whereas all three aortic 
valves in the CB2
-/- transplanted animal are filled with   
large atherosclerotic lesions, in the WT transplanted animal 
one aortic valve is virtually free of atherosclerotic lesions 
(Fig. 3A, valve B). Since different locations in the vascula-
ture differ in their propensity to develop atherosclerotic   
lesions, due to e.g. location or differences in shear stress 
[19], we analyzed the lesion size for each aortic valve sepa-
rately. The aortic valve that demonstrated delayed plaque 
formation was found to contain significantly larger lesions in 
Table 1. Effect of Bone Marrow Transplantation on Chimerism and White Blood Cell Composition, as Measured by Quantitative 
PCR and FACS Analysis, Respectively 
 WT  Transplanted  CB2-/-  Transplanted 
White blood cells of donor origin (% chimerism)  94.2 ± 1.4  94.0 ± 0.7 
T-cells (%)  24.7 ± 7.8  23.0 ± 9.3  
B-cells (%)  51.0 ± 8.2  53.9 ± 5.8 
Monocytes (%)  10.4 ± 3.3  7.7 ± 2.3 
Granulocytes (%)  8.7 ± 4.1  7.1 ± 1.4 
WT CB2-/- WT CB2-/- WT CB2-/- WT CB2-/-
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Fig. (2). A) Representative photomicrographs of Oil Red O stained aortic arches derived from a WT transplanted animal (left panel) and a 
CB2-/- transplanted animal (right panel). Dark red staining indicates an atherosclerotic lesion. B) The atherosclerotic lesion area measured in 
the aortic arch by quantification of Oil red O staining. Shown is the percentage of the aortic arch covered with an atherosclerotic lesion for 
each individual animal. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Representative photomicrographs of the aortic valve area of a WT transplanted LDLr-/- mouse (panel A) and a CB2-/- transplanted 
LDLr-/- mouse (panel B) stained with haematoxylin-eosin (magnification 20x). Note that in the CB2-/- transplanted animal all three aortic 
valves are filled with an atherosclerotic plaque, whereas in the WT transplanted animal one aortic valve is virtually free of atherosclerotic 
lesions. C) The atherosclerotic lesion area measured in the entire aortic valve area. Shown is the average atherosclerotic lesion size in the 
aortic root for each individual animal. D) The atherosclerotic lesion area measured per aortic valve. Shown is the average atherosclerotic le-
sion size per aortic valve for each individual animal. The valves were indicated A, B, and C arbitrarily, however, care was taken that for each 
animal A, B and C had the same orientation in the heart. 
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CB2
-/- transplanted animals (0.13 ± 0.07 m
2) as compared 
to WT transplanted mice (0.08 ± 0.05 m
2, Fig. 3C). 
  Thus, although 12 weeks of high fat diet feeding caused 
massive atherosclerosis development in the aortic root of   
all animals, haematopoietic CB2 deficiency enhances   
plaque formation in the location in the heart that normally 
shows slightly delayed atherosclerosis development, thereby  
corroborating the data obtained from the aortic arch. 
Haematopoietic CB2 Deficiency May Enhance Athero-
sclerosis Plaque Severity 
  Atherosclerosis severity was qualified in the aortic valve 
area of the heart by sorting plaques in the categories [18]: I) 
early fatty streak, II) regular fatty streak, III) mild plaque, 
IV) moderate plaque, V) severe plaque. When all plaques 
were taken into account, no difference was found in the dis-
tribution over the lesion categories between CB2
-/- and WT 
transplanted animals (Fig. 4A). Most of the atherosclerotic 
lesions are severe plaques and only a limited number of fatty 
streaks was found in both animal groups, supporting the con-
clusion that atherogenesis was advanced in both groups. 
  In the aortic valve with delayed atherogenesis, i.e. valve 
B (Fig. 4B), the distribution of the plaques over different 
lesion types was indicative of earlier lesions; the majority of 
plaques was categorised as fatty streaks and mild plaques. In 
valve B, CB2
-/- transplanted animals showed less fatty 
streaks and more mild to severe plaques than WT trans-
planted animals. This difference, however, did not reach 
statistical significance (p=0.08). 
  In addition to plaque severity, several parameters of 
plaque composition were profiled for all lesions. There was 
no difference between CB2
-/- and WT transplanted animals 
with regard to the lesion content of collagen, necrosis and 
monocyte adherence (data not shown). The amount of in-
flammatory infiltrates containing small macrophages seemed 
to be higher in CB2
-/- compared to WT transplanted animals 
(score 2.18 ± 0.88, versus 1.78 ± 1.00, respectively), how-
ever, this difference was not significant (p=0.29). On the 
contrary, the amount of large foam cells was significantly 
lower in CB2
-/- compared to WT transplanted animals (score 
2.56 ± 0.70, versus 2.06 ± 0.56, respectively; p=0.04; see 
Fig. 4C and D for representative photomicrographs of large 
foam cell areas and inflammatory infiltrates). 
  These data together might suggest that CB2 deficiency 
enhances plaque severity and the inflammatory phenotype of 
an atherosclerotic lesion. 
DISCUSSION 
  In the present study, the role of haematopoietic CB2 de-
ficiency on atherosclerosis development in LDLr
-/- mice was 
examined. The results show that CB2 deficiency aggravates 
atherosclerosis in the early stages, as measured in the aortic 
root and arch. However, when atherosclerosis is developed 
to a severe level, lack of CB2 does not further enhance athe-
rosclerosis. Thus, endocannabinoid signalling via CB2 seems 
to have a protective effect in atherosclerosis development. 
  The current study confirms previously reported data 
demonstrating that THC, a general cannabinoid receptor 
agonist, can inhibit development of atherosclerosis in ApoE
-/- 
mice [14]. Using genetic ablation of CB2 we have now dem-
onstrated that at least part of the effects observed using THC 
is highly likely mediated through CB2. CB2 deficiency re-
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). A) Lesion severity in the aortic valve area presented as percentage of all plaques (I. early fatty streak, II. regular fatty streak, III. 
mild plaque, IV. moderate plaque, V. severe plaque). B) Lesion severity of the plaques in valve B as percentage of all plaques in valve B. 
Representative photomicrographs of an atherosclerotic lesion containing: C) large foam cells or D) inflammatory infiltrates with small 
macrophages stained with haematoxylin-eosin (magnification 40x). 20    The Open Cardiovascular Medicine Journal, 2011, Volume 5  Delsing et al. 
sulted in aggravation of early atherosclerosis, not showing an 
effect on late atherosclerosis, while treatment with THC 
showed an effect on both early atherosclerosis and existing 
atherosclerotic lesions [14]. This difference could be ex-
plained by the properties of THC, which has been shown to 
bind to both CB1 and CB2. Since CB1 has been detected on 
inflammatory cells as well, it is very well possible that THC 
could exert additional non-CB2 mediated effects on athero-
genesis. For example, recent studies showed that a cannabi-
noid receptor agonist (WIN55, 212) enhanced the accumula-
tion of cholesterol in macrophages via the CB1 receptor [20]. 
Additionally, THC has been described to function as a ligand 
of the nuclear receptor peroxisome proliferator-activated 
receptor gamma (PPAR), via which it could cause vasore-
laxation and exert cardioprotective effects [15]. However, in 
vitro, some of the anti-atherosclerotic effects of THC can be 
blocked by a selective CB2 antagonist [14], suggesting that 
THC would exert its effect mainly via CB2. 
  Alternatively, the difference between our study and the 
work of Steffens and coworkers could be explained by the 
two different mouse models that were used. It has been de-
scribed that atherosclerotic lesion development in the aortic 
root is faster in LDLr
-/- mice as compared to the ApoE
-/- mice 
used by Steffens et al.  [14], causing the atherosclerosis in 
the aortic arch to be more advanced in the current study. 
  Different mechanisms of action may underlie the effect 
of haematopoietic CB2 deficiency in development of athero-
sclerosis. Our studies show that the effect is not due to ele-
vated plasma cholesterol levels or changed white blood cell 
compositions, since there were no differences found in these 
parameters for the WT and CB2
-/- transplanted animals. With 
respect to plaque composition parameters, our study showed 
a slightly enhanced amount of inflammatory infiltrates and a 
significantly reduced amount of foam cells in the CB2
-/- 
transplanted animals. It has been reported that CB1 agonism 
can enhance macrophage cholesterol accumulation [20]. 
Whether CB2 antagonism or deficiency blocks cholesterol 
uptake and thereby reduces foam cell formation remains to 
be investigated. To our opinion, it is most likely that aggra-
vation of early atherosclerosis in CB2
-/- transplanted mice is 
induced by increased monocyte migration into the vessel 
wall or reduced macrophage apoptosis propensity. 
  One of the hallmark processes in early atherosclerosis is 
the migration of monocytes from the circulation into the vas-
cular wall, after which differentiation into a macrophage 
enables the cell to start accumulating lipids. A number of 
studies have shown that cannabinoids can influence mono-
cyte or macrophage migration. The endocannabinoid 2-
arachidonoylglycerol (2-AG) has been found to act as a 
chemoattractant for monocytes [21], whereas synthetic 
ligands for the cannabinoid receptor generally do not possess 
chemoattractant properties. These synthetic cannabinoids, 
however, are often described to be able to inhibit monocyte 
migration induced by either endocannabinoids or chemoki-
nes [10, 14, 21]. The fact that also CB2 inverse agonists have 
been described to reduce monocyte migration [9, 22], sug-
gests that the mere removal of a cannabinoid gradient is 
enough to [10, 14, 21] influence migration [23]. The migra-
tion modulatory effects of cannabinoids have been ascribed 
to the CB2 receptor mainly by the finding that the selective 
CB2 antagonist SR144528 can inhibit the effects. To rule out 
the possibility that conclusions are drawn on the basis of 
aspecific effects of cannabinoid compounds, our investiga-
tion using CB2 knockout mice was warranted. 
  Very recently, it was discovered that CB2 expression on 
the macrophage enhances the propensity to go into apoptosis 
upon treatment with oxidised low density lipoproteins 
(OxLDL). CB2 deficient macrophages were found to be re-
sistant to OxLDL-induced apoptosis [24]. The consequences 
of macrophage apoptosis in an atherosclerotic lesion are 
multiple: there is strong evidence that macrophage apoptosis 
reduces early lesion formation, but can aggravate atheroscle-
rosis in advanced lesions [25]. 
  Another key inflammatory process in which a function 
for the CB2 receptor has been documented, is the secretion 
of cytokines. For many of these cytokines, a proatherogenic 
(e.g. TNF) or antiatherogenic (e.g. IL-10) role has been 
reported (reviewed in [26]). The balance in pro-
inflammatory (e.g. IFN, TNF, IL-6) and anti-inflammatory 
(e.g. IL-10) cytokines has been suggested to be shifted to the 
anti-inflammatory side by cannabinoids [27], however, the 
opposite effect has also been reported [27, 28]. So in vivo, 
cannabinoids might suppress or increase production of pro-
inflammatory cytokines [11], making it difficult to speculate 
on the effects of cytokine modulation by CB2 deficiency in 
atherosclerosis. 
  Taken together, this is the first study investigating the 
role of the CB2 receptor in atherosclerosis, using the CB2 
deficient mouse. The authors Mach and Steffens already 
posed a hypothesis that endocannabinoid signalling could 
affect atherogenesis [29]. The current study shows that a lack 
of endocannabinoid signalling via the CB2 receptor in hae-
matopoietic cells enhances early atherogenesis in LDL re-
ceptor deficient mice. These data suggest that enhancement 
of CB2 signalling, either by raising endocannabinoid levels 
or treatment with a selective CB2 agonists, can form a novel 
treatment of atherosclerosis. 
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